Thomas I.F.H. Cremers

Author

Also Known As

T Cremers, T. Cremers, T.I. Cremers, T.I.F.H. Cremers, Thomas Cremers, Thomas I Cremers, Thomas I F H Cremers, Thomas I. Cremers, Thomas I. F. H. Cremers, Thomas I.F.H Cremers

Publications

Citations

H-Index

Concepts

All Affiliations

University of Groningen Wolters Kluwer (Netherlands)University Medical Center Groningen Lundbeck (Denmark)AVL (France)

About

Thomas I.F.H. Cremers is an author at University of Groningen specializing in medicine, neuropharmacology, and neuroscience.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	26	1.3K
2	Social Sciences	17	19	935
3	Engineering	3	3	140
4	Health Sciences	2	2	135
5	Public Health	1	1	19

Thomas I.F.H. Cremers

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
(–)-(1 R,2 R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties Thomas Tzschentke, Thomas Christoph, Babette Kögel, Journal of Pharmacology and Experimental Therapeutics	2007	389
Pre‐clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence Hans Rollema, Alka Shrikhande, KM Ward, British Journal of Pharmacology	2010	162
Inactivation of 5-HT2C Receptors Potentiates Consequences of Serotonin Reuptake Blockade Thomas I.F.H. Cremers, Marco Giorgetti, Fokko J. Bosker, Neuropsychopharmacology Molecular PharmacologyFunctional SelectivityMedicineNeurotransmitterNeuropharmacology	2004	157
Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—A rat microdialysis and electrophysiology study Alan L. Pehrson, Thomas I.F.H. Cremers, Cécile Betry, European Neuropsychopharmacology Lu Aa21004PsychiatryMedicineNeurotransmitterNovel Multimodal Antidepressant	2012	155
S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models Anne Dekeyne, Clotilde Mannoury la Cour, Alain P. Gobert, Psychopharmacology PsychiatryFunctional SelectivityMedicineAnxiolytic PropertiesDepression	2008	124
Augmentation of SSRI Effects on Serotonin by 5-HT2C Antagonists: Mechanistic Studies Thomas I.F.H. Cremers, Kieran Rea, Fokko J. Bosker, Neuropsychopharmacology 5-Ht2c AntagonistsMechanistic StudiesPsychoactive DrugPsychiatryMedicine	2007	84
Cerebrospinal fluid monoamine and metabolite concentrations and aggression in rats Bea J van der Vegt, Natasja G. Lieuwes, Thomas I.F.H. Cremers, Hormones and Behavior Behavioral SciencesBehavioral NeuroscienceAddictionPsychopharmacologyNeuropharmacology	2003	79
S33138 (N-[4-[2-[(3 aS,9 bR)-8-cyano-1,3 a,4,9 b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenyl-acetamide), a Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: III. Actions in Models of Therapeutic Activity and Induction of Side Effects Mark J. Millan, Florence Loiseau, Anne Dekeyne, Journal of Pharmacology and Experimental Therapeutics	2007	78
Regulation of the release of serotonin in the dorsal raphe nucleus by α<sub>1</sub> and α<sub>2</sub> adrenoceptors Olga L. Pudovkina, Thomas I.F.H. Cremers, Ben H.C. Westerink Synapse NeuropeptidesNeurotransmitterNeurotransmissionNeuroendocrine MechanismNeurochemistry	2003	71
ORIGINAL RESEARCH—BASIC SCIENCE: Acute and Repeated Flibanserin Administration in Female Rats Modulates Monoamines Differentially Across Brain Areas: A Microdialysis Study Kelly A. Allers, Eliyahu Dremencov, Angelo Ceci, The Journal of Sexual Medicine	2010	68

Page 1